NZ712670B2 - Progesterone receptor antagonist dosage form - Google Patents
Progesterone receptor antagonist dosage form Download PDFInfo
- Publication number
- NZ712670B2 NZ712670B2 NZ712670A NZ71267014A NZ712670B2 NZ 712670 B2 NZ712670 B2 NZ 712670B2 NZ 712670 A NZ712670 A NZ 712670A NZ 71267014 A NZ71267014 A NZ 71267014A NZ 712670 B2 NZ712670 B2 NZ 712670B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- estra
- methylsulphonyl
- pentafluoroethyl
- hydroxy
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title claims description 9
- 102000003998 progesterone receptors Human genes 0.000 title abstract description 17
- 108090000468 progesterone receptors Proteins 0.000 title abstract description 17
- 239000002464 receptor antagonist Substances 0.000 title abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 39
- 206010046798 Uterine leiomyoma Diseases 0.000 claims abstract description 36
- 201000010260 leiomyoma Diseases 0.000 claims abstract description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 22
- 210000004291 Uterus Anatomy 0.000 claims abstract description 17
- 230000000069 prophylaxis Effects 0.000 claims abstract description 16
- 201000004458 myoma Diseases 0.000 claims abstract description 14
- 201000007954 uterine fibroid Diseases 0.000 claims abstract description 14
- 201000009273 endometriosis Diseases 0.000 claims abstract description 11
- 230000002175 menstrual Effects 0.000 claims abstract description 10
- 239000011780 sodium chloride Substances 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 32
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- -1 Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone Chemical compound 0.000 claims description 17
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 14
- 206010046788 Uterine haemorrhage Diseases 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 32
- 239000006186 oral dosage form Substances 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 description 63
- 206010018987 Haemorrhage Diseases 0.000 description 22
- 230000000740 bleeding Effects 0.000 description 22
- 231100000319 bleeding Toxicity 0.000 description 22
- 239000003826 tablet Substances 0.000 description 18
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 239000000583 progesterone congener Substances 0.000 description 8
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 7
- 239000000186 progesterone Substances 0.000 description 7
- 229960003387 progesterone Drugs 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 230000002357 endometrial Effects 0.000 description 5
- 239000000546 pharmaceutic aid Substances 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 210000004696 Endometrium Anatomy 0.000 description 4
- 230000003042 antagnostic Effects 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 229960005309 Estradiol Drugs 0.000 description 3
- 229940095743 Selective estrogen receptor modulators Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 201000000736 amenorrhea Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003111 delayed Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 206010014756 Endometrial hypertrophy Diseases 0.000 description 2
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 229960002258 Fulvestrant Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 229940040129 Luteinizing Hormone Drugs 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N Mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
- 102000000623 Oestrogen receptor Human genes 0.000 description 2
- 108050008051 Oestrogen receptor Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000001833 anti-estrogenic Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 230000002860 competitive Effects 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229960003248 mifepristone Drugs 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 239000002379 progesterone receptor modulator Substances 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000006213 vaginal ring Substances 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- METQSPRSQINEEU-HXCATZOESA-N (1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0^{2,4}.0^{5,10}.0^{14,19}.0^{16,18}]nonadecane-15,2'-oxolan]-5-ene-5',7-dione Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 1
- ORKBYCQJWQBPFG-WOMZHKBXSA-N (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ORKBYCQJWQBPFG-WOMZHKBXSA-N 0.000 description 1
- WNSDZLZVSSOOCA-WOMZHKBXSA-N (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one;(8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WNSDZLZVSSOOCA-WOMZHKBXSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 1
- FXBOKASTQKMONI-UHFFFAOYSA-N 2-methyl-5-(2-methylphenoxy)benzenesulfonic acid Chemical class CC1=CC=CC=C1OC1=CC=C(C)C(S(O)(=O)=O)=C1 FXBOKASTQKMONI-UHFFFAOYSA-N 0.000 description 1
- WIFPJDJJFUSIFP-UHFFFAOYSA-N 4-aminobutane-1,2,3-triol Chemical compound NCC(O)C(O)CO WIFPJDJJFUSIFP-UHFFFAOYSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N Bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Chemical class 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 229960003608 Clomifene Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N Clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960000978 Cyproterone Acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N Cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229960002887 Deanol Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N Desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 229940096516 Dextrates Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N Etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 1
- 229960002598 Fumaric acid Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229960005352 Gestodene Drugs 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N Gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 229960002442 Glucosamine Drugs 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 229940030482 HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Drugs 0.000 description 1
- 229960003284 Iron Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N Lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical class OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 210000000754 Myometrium Anatomy 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N N-benzyl-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 229940100662 Nasal Drops Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N Norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- XZEUAXYWNKYKPL-URLMMPGGSA-N Ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 1
- 229940030490 PROGESTOGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M Potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- WWYNJERNGUHSAO-XUDSTZEESA-N Previfem Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229940095055 Progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 229940095574 Propionic acid Drugs 0.000 description 1
- 229960004622 Raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229940044953 Vaginal Ring Drugs 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960000817 bazedoxifene Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 description 1
- 229960003309 dienogest Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004845 drospirenone Drugs 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940046079 endocrine therapy drugs Progestogens Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000001076 estrogenic Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Chemical class 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100001045 histological change Toxicity 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 230000003463 hyperproliferative Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229910000460 iron oxide Inorganic materials 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Chemical class 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Chemical class 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- XGZVLEAZGCUUPH-UHFFFAOYSA-N methylamino(methylimino)methanesulfonic acid Chemical class CNC(=NC)S(O)(=O)=O XGZVLEAZGCUUPH-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 229960000993 norethisterone Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 239000003217 oral combined contraceptive Substances 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960003327 ormeloxifene Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000069 poly(p-phenylene sulfide) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001850 reproductive Effects 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine zwitterion Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 229940095745 sex hormones and modulators of the genital system Progesterone receptor modulators Drugs 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 125000005373 siloxane group Chemical group [SiH2](O*)* 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000001117 sulphuric acid Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Chemical class 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000009810 tubal ligation Methods 0.000 description 1
- 229960000499 ulipristal acetate Drugs 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Abstract
The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11 β,17β)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one at the dosage of about 0.5 to 5 mg and more particularly 2 mg. Additionally, the invention is directed to the use of the novel pharmaceutical composition for treatment of and/or prophylaxis of gynaecological diseases, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds, and method for obtaining such composition and oral dosage form. directed to the use of the novel pharmaceutical composition for treatment of and/or prophylaxis of gynaecological diseases, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds, and method for obtaining such composition and oral dosage form.
Description
Progesterone receptor antagonist dosage form
The disclosure is directed to a pharmaceutical composition comprising a progesterone receptor antagonist
namely (11β,17β)Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone at
the dosage of about 0.5 to 5 mg and more particularly 2 mg. Additionally, the disclosure is directed to the
use of the novel pharmaceutical composition for treatment of and/or prophylaxis of gynaecological
diseases, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive
menstrual bleeds, and method for obtaining such composition and oral dosage form.
Background
Uterine leiomyomas (also called fibroids or myomas) are common benign tumors of the myometrium, which
are reported to occur in approximately 30-40 % of all women of reproductive age. They may remain
asymptomatic, or cause bleeding abnormalities and/or bulk-related symptoms depending on their number,
size and location. Various medications are used for symptom-oriented therapy in minor disease (e.g.
combined oral contraceptives, progestogens, iron supplements). For short-term therapy and/or as a
precursor to surgery, gonadotropin-releasing hormone agonists represent the most effective medical
treatment. However, their use is restricted to 6 months due to hypoestrogenic side effects. For definite
treatment of symptomatic leiomyomas, therapeutic options are mainly surgical so far.
Various studies suggested steroid-dependence of fibroids growth in which progesterone has a critical role.
This is supported by the fact, that progesterone receptor (PR) antagonists – like mifepristone (RU 486) –
have been shown to decrease the size of fibroids and related symptoms. Therefore, PR antagonists might
offer a promising therapeutic alternative meeting the need for medical long-term treatment of symptomatic
fibroids with an orally effective agent lacking clinically relevant side effects. Mifepristone (RU 486) was
disclosed in EP57115. Additional competitive progesterone receptor modulators are shown below.
from Spitz et al. Current Opinion in Obstetrics and Gynecology, 2009, 21:318-324.
All these compounds as listed above are effective in the treatment of uterine fibroids where that are
associated with a reduction in pain, bleeding and improvement in quality of life and decrease in fibroid size.
Long-term treatments are associated with endometrial thickening on ultrasound and histological changes in
the endometrium. The endometrial change such as endometrial thickening seems to be connected to cystic
glandular dilatation (Spitz et al. Current Opinion in Obstetrics and Gynecology, 2009, 21:318-324.).
Progesterone receptor antagonists with a fluorinated 17 -side chain were published in WO 98/34947 and
Fuhrmann et al., J. Med. Chem. 43, 5010 - 5016 (2000).
In PEARL I and PEARL II trial (N Engl J Med. 2012;366:409-420) women with excessive uterine bleeding
due to the presence of fibroids were randomized to ulipristal acetate (5 mg vs. 10 mg orally once daily) vs.
placebo or intramuscular injections of leuprolide acetate for up to 13 weeks.
To conclude, endometrium changes were observed during treatment with most of the cited above
progesterone receptor antagonists.
It was surprisingly found that (11β,17β)Hydroxy[4-(methylsulphonyl)phenyl]
(pentafluoroethyl)estra-4,9-dienone is a potent competitive progesterone receptor antagonist creating
alternatives for the treatment of gynaecological diseases. Amenorrhea was observed in healthy subjects
treated with said compound. (11β,17β)Hydroxy[4-(methylsulphonyl)phenyl]
(pentafluoroethyl)estra-4,9-dienone was originally disclosed in WO2011/009531A1. Further, it was
surprisingly found that the dosage of about 0.5 to 5 mg and more particularly 2 mg of (11β,17β)
Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone that is a potent
progesterone receptor antagonist being useful for the treatment of certain gynaecological diseases wherein
the gynaecological disease is preferably characterized by excessive uterine bleeding. Indeed, it was
observed an amenorrhea (non-bleeding) of 92.5% in the healthy subjects to which said compound was
administered at a dosage of 2 mg. Amenorrhea corresponds to the major objective of the treatment i.e.
control of excessive uterine bleeding.
In the case of the present invention further improvements were observed in respect of the return of
bleeding after the end of treatment and the endometrium thickness.
Summary
The invention is directed to use of (11β,17β)Hydroxy[4-(methylsulphonyl)phenyl]
(pentafluoroethyl)estra-4,9-dienone or salts thereof in the manufacture of a medicament for treatment
and/or prophylaxis of a gynaecological disease, wherein the medicament comprises about 1 to 5 mg of
(11β,17β)Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone.
Described is a pharmaceutical composition comprising about 0.5 to 5 mg of (11β,17β)Hydroxy[4-
(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone and treatment and/or prophylaxis of
gynaecological diseases in patients in need wherein the gynaecological disease is preferably characterized
by excessive uterine bleeding.
Also described is a pharmaceutical composition comprising about 2 mg of (11β,17β)Hydroxy[4-
(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone and treatment and/or prophylaxis of
gynaecological diseases in patients in need wherein the gynaecological disease is preferably characterized
by excessive uterine bleeding.
Further, described is an oral dosage form comprising about 2 mg of (11β,17β)Hydroxy[4-
(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone and treatment and/or prophylaxis of
gynaecological diseases in patients in need wherein the gynaecological disease is preferably characterized
by excessive uterine bleeding.
Finally, described is a method for obtaining said pharmaceutical composition or oral dosage form.
The compound described herein is defined as a selective progesterone receptor modulator with well
confirmed antagonist property.
Description
In a first aspect, the invention is directed to use of (11β,17β)Hydroxy[4-(methylsulphonyl)phenyl]-
17-(pentafluoroethyl)estra-4,9-dienone or salts thereof in the manufacture of a medicament for treatment
and/or prophylaxis of a gynaecological disease, wherein the medicament comprises about 1 to 5 mg of
(11β,17β)Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone.
Also described is a pharmaceutical composition comprising about 0.5 to 5 mg of (11β,17β)Hydroxy
[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone
of formula
or salts thereof.
Preferably, the pharmaceutical composition comprises a range of about 0.7 to 5 mg, 0.7 to 4.5 mg, 1 to 4.5
mg, 1 to 4 mg, 1.5 to 3.5 mg or 1.5 to 3 mg of above mentioned compound or salt thereof independently
from each other. More preferably, the pharmaceutical composition comprises a range of about 0.7 to 5 mg,
1 to 4 mg or 1.5 to 3 mg of above mentioned compound or salt thereof independently from each other.
Even more preferably, the pharmaceutical composition comprises a range of about 1 to 4 mg of above
mentioned compound or salt thereof.
Preferably, the pharmaceutical composition comprises 0.5 mg, 0.7 mg, 1 mg, 2 mg, 3 mg, 4 mg, or 5 mg of
above mentioned compound or salt thereof. More preferably, the pharmaceutical composition comprises 2
mg, 3 mg or 4 mg of above mentioned compound or salt thereof.
Even more preferably, described is a pharmaceutical composition comprising about 2 mg of (11β,17β)
Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone
of formula
or salts thereof.
In a first embodiment, the pharmaceutical composition comprises additionally a pharmaceutically
acceptable excipient.
Pharmaceutically acceptable excipient is defined as a filler (such as sugars, such as lactose, sucrose,
dextrose and dextrates; sugar alcohols, such as mannitol, sorbitol and xylitol); carbonates and phosphates
of alkaline earth metals, such as calcium carbonate and calcium phosphate; celluloses, such as powdered
cellulose and microcrystalline cellulose; colloidal silica; titanium dioxide; kaolin; talc), or lubricants (such as
magnesium stearate).
In a second embodiment, the pharmaceutical composition comprises additionally a pharmaceutically
acceptable excipient and/or at least one or more other active substances, in particular active substances
known for the treatment and/or prophylaxis of the aforementioned diseases.
For the treatment of fibroids of the uterus or endometriosis, the compound described herein can be
combined simultaneously or sequentially with gestagens or combinations of oestrogens and gestagens.
Progesterone receptor antagonists/gestagen regimens are disclosed in WO 96/15794 (Spicer et al.,
Balance Pharm. Inc.), WO 96/03130 (Stöckemann et al., Schering AG) and (Möller et
al., Bayer Schering Pharma AG). Regimens – optionally repeated – in which the progesterone receptor
antagonist is administered over a period of two to four months, followed by the administration of the
gestagen for a period of one to four weeks, are very suitable for the treatment of fibroids of the uterus and
endometriosis. Administration of the progesterone receptor antagonist for 84 days, followed by
administration of the gestagen for 14 days – optionally repeated – is especially suitable.
Simultaneous or sequential administration of the compounds described herein e.g. with SERMs, SERDs
and oestrogens can be considered for the treatment of complaints associated with the menopause.
SERMs (selective estrogen receptor modulators) are compounds that are tissue selective and have either
an anti-oestrogenic or oestrogenic action, for example on the uterus they inhibit the action of oestrogen, but
on bone they have a neutral or oestrogen-like action. Examples are clomifene, raloxifene, tamoxifen,
torimifene, bazedoxifene, lasofoxifene and ormeloxifene.
Selective estrogen receptor destabilizers (SERD) are pharmaceuticals which completely antagonize the
oestrogen receptor ('pure anti-oestrogens' without oestrogenic active component) and lead to down-
regulation of the receptor (for example fulvestrant, ZK-703 and ZK-253 (Hoffmann J et al., J Natl Cancer
Inst 2004, 96:210-218) and compounds described in WO 98/007740, WO 99/33855 and WO 03/045972.
Anti-oestrogens are compounds that completely antagonize the oestrogen receptor, for example
fulvestrant.
Gestagens are, in the sense of the present invention, either the natural progesterone itself or synthetic
derivatives, which like progesterone itself bind to the progesterone receptor and, at dosages above the
ovulation inhibiting dose, inhibit ovulation. As examples of the synthetic derivatives, we may mention
drospirenone, gestodene, levonorgestrel, cyproterone acetate, desogestrel and 3-ketodesogestrel,
norethisterone, norethisterone acetate and dienogest.
Combinations of gestagens and oestrogens are the combinations of active substances that are contained
in the oral contraceptives that are known per se, for example Yasmin, Femovan, Triquilar, Marvelon, YAZ
etc.
The description encompasses all salts, solvates or solvates of the salts, including all crystal modifications of
(11β,17β)Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone.
The pharmaceutical composition is in an appropriate form for intravenous (i.v.), intramuscular (i.m.) or oral
administration. Preferably, oral form for administration is a dosage form such as tablet capsule or solution.
Nevertheless, it may optionally be necessary to deviate from the stated amounts, namely depending on
body weight, route of administration, individual response to the active substance, type of preparation and
point of time or interval when application takes place. Thus, in some cases it may be sufficient to use less
than the aforementioned minimum amount, whereas in other cases the stated upper limit must be exceeded. In
the case of the administration of larger amounts it may be advisable to distribute these in several individual
doses throughout the day.
(11β,17β)Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone is
referenced as compound 1 within the whole specification.
It shall be understood that the dosage “about 2 mg” means any dosage from 1.5 to 2.5 mg of compound 1.
Preferably, the dosage is of 2 mg of compound 1.
The compound 1 described herein displays an unforeseeable, valuable pharmacological, pharmacokinetic
and pharmacodynamic profile of action.
Also described is a pharmaceutical composition useful for the treatment and/or prophylaxis of
gynaecological diseases. The gynaecological disease is preferably characterized by excessive uterine
bleeding. More preferably, the gynaecological disease is fibroids of the uterus (myomas, uterine
leiomyoma), endometriosis or excessive menstrual bleeds. Even more preferably, the gynaecological
disease is fibroids of the uterus (myomas, uterine leiomyoma).
In other word described is a method for the treatment and/or prophylaxis of gynaecological diseases with
the administration to a patient in need of a pharmaceutical composition comprising about 0.5 to 5 mg of
(11β,17β)Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone or salts
thereof. The gynaecological disease is preferably characterized by excessive uterine bleeding. More
preferably, the gynaecological disease is fibroids of the uterus (myomas, uterine leiomyoma),
endometriosis or excessive menstrual bleeds. Even more preferably, the gynaecological disease is fibroids
of the uterus (myomas, uterine leiomyoma).
Preferably, the pharmaceutical composition comprises a range of about 0.7 to 5 mg, 0.7 to 4.5 mg, 1 to 4.5
mg, 1 to 4 mg, 1.5 to 3.5 mg or 1.5 to 3 mg of above mentioned compound or salt thereof independently
from each other. More preferably, the pharmaceutical composition comprises a range of about about 0.7 to
mg, 1 to 4 mg or 1.5 to 3 mg of above mentioned compound or salt thereof independently from each
other. Even more preferably, the pharmaceutical composition comprises a range of about 1 to 4 mg of
above mentioned compound or salt thereof.
Preferably, the pharmaceutical composition comprises 0.5 mg, 0.7 mg, 1 mg, 2 mg, 3 mg, 4 mg, or 5 mg of
above mentioned compound or salt thereof. More preferably, the pharmaceutical composition comprises 2
mg, 3 mg or 4 mg of above mentioned compound or salt thereof.
More particularly, described is a method for the treatment and/or prophylaxis of gynaecological diseases
with the administration to a patient in need of a pharmaceutical composition comprising about 2 mg of
(11β,17β)Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone or salts
thereof. The gynaecological disease is preferably characterized by excessive uterine bleeding. More
preferably, the gynaecological disease is fibroids of the uterus (myomas, uterine leiomyoma),
endometriosis or excessive menstrual bleeds. Even more preferably, the gynaecological disease is fibroids
of the uterus (myomas, uterine leiomyoma).
Also described is an oral dosage form comprising about 0.5 to 5 mg of (11β,17β)Hydroxy[4-
(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone
of formula
or salts thereof.
Preferably, the pharmaceutical composition comprises a range of about 0.7 to 5 mg, 0.7 to 4.5 mg, 1 to 4.5
mg, 1 to 4 mg, 1.5 to 3.5 mg or 1.5 to 3 mg of above mentioned compound or salt thereof independently
from each other. More preferably, the pharmaceutical composition comprises a range of about 0.7 to 5 mg,
1 to 4 mg or 1.5 to 3 mg of above mentioned compound or salt thereof independently from each other.
Even more preferably, the pharmaceutical composition comprises a range of about 1 to 4 mg of above
mentioned compound or salt thereof.
Preferably, the pharmaceutical composition comprises 0.5 mg, 0.7 mg, 1 mg, 2 mg, 3 mg, 4 mg, or 5 mg of
above mentioned compound or salt thereof. More preferably, the pharmaceutical composition comprises 2
mg, 3 mg or 4 mg of above mentioned compound or salt thereof.
More particularly, described is an oral dosage form comprising about 2 mg of (11β,17β)Hydroxy[4-
(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone
of formula
or salts thereof.
In a first embodiment, the oral dosage form comprises additionally a pharmaceutically acceptable excipient.
In a second embodiment, the oral dosage form comprises additionally a pharmaceutically acceptable
excipient and/or at least one or more other active substances, in particular active substances known for the
treatment and/or prophylaxis of the aforementioned diseases.
Embodiment and preferred features as described above are herein included.
Further, described is an oral dosage form as described in third aspect for the treatment and/or prophylaxis
of gynaecological diseases. The gynaecological disease is preferably characterized by excessive uterine
bleeding. More preferably, the gynaecological disease is fibroids of the uterus (myomas, uterine
leiomyoma), endometriosis or excessive menstrual bleeds. Even more preferably, the gynaecological
disease is fibroids of the uterus (myomas, uterine leiomyoma).
Embodiment and preferred features as described above are herein included.
Finally, described is a method for obtaining said pharmaceutical composition or oral dosage form as
described above.
Embodiment and preferred features as described above are herein included.
Definitions and Preferred features applicable to first to fourth aspect:
Physiologically harmless salts of the compounds described herein are preferred as salts within the scope of the
present invention. However, salts that are not suitable in themselves for pharmaceutical uses, but can for
example be used for the isolation or purification of the compounds described herein, are also covered.
Physiologically harmless salts of the compounds described herein comprise – when they contain a basic
function – salts with inorganic or organic acids, in particular of mineral acids, carboxylic acids and sulphonic
acids, e.g. salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid,
ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalene-disulphonic acid, acetic
acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid
and benzoic acid.
Physiologically harmless salts of the compounds described herein comprise – when they contain an acid
function – alkali metal salts, alkaline earth metal salts or ammonium salts, such as can be obtained by reaction
with corresponding inorganic or organic bases. We may mention, for example and preferably, alkali metal salts
(e.g. sodium and potassium salts), alkaline earth metal salts (e.g. calcium and magnesium salts) and
ammonium salts, derived from ammonia or organic amines with 1 to 16 carbon atoms, such as, for example
and preferably, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine,
diethanolamine, triethanolamine, bicyclo-hexylamine, dimethylamino-ethanol, procaine, dibenzylamine, N-
methylmorpholine, arginine, lysine, ethylenediamine, N-methyl piperidine, N-methyl glucamine, D-methyl
glucamine, ethyl glucamine, 1,6-hexadiamine, glucosamine, N-methylglycine, 2-amino-1,3-propandiol, tris-
hydroxymethyl-aminomethane and 1-amino-2,3,4-butanetriol.
Those forms of the compounds described herein that display, in the solid or liquid state, adduct formation with
solvent molecules, are designated as solvates. The solvent can be present in stoichiometric or even non-
stoichiometric proportions. In the case of stoichiometric solvates, they are also called hemi-, (semi-), mono-
, sesqui-, di-, tri-, tetra-, penta-, etc. solvates. Hydrates are a special form of solvates, in which the
coordination takes place with water.
The pharmaceutical efficacy of the compound described herein can be explained by their action as
progesterone receptor antagonists, and thus by their antagonizing action on the progesterone receptor.
Also described is the use of the compound described herein for the treatment and/or prophylaxis of
diseases based on hormone-dependent hyperproliferative processes, preferably of gynaecological
diseases, in particular of fibroids of the uterus, endometriosis or hormone-dependent breast cancers.
The compounds described herein can act systemically and/or locally. For this purpose they can be applied
in a suitable way, e.g. by the oral, intrauterine, intravaginal, parenteral, pulmonary, nasal, sublingual,
lingual, buccal, rectal, dermal, transdermal, conjunctival, or otic route or as an implant or stent.
Intrauterine means in particular application by means of an IUS (intrauterine system) or IUD (intrauterine
device). Intravaginal application can be effected by means of, among others, IVR/VRS (intravaginal
ring/vaginal ring system).
Forms for intrauterine or intravaginal application (cf. e.g. WO 01/47490, especially page 1, line 10 to line 5,
line 13 and line 7, line 19 to line 58, line 6, or for vaginal rings: WO 06/010097, especially page 10, line 22
to page 14, line 28) can contain the compounds described herein and non-silicone and/or silicone polymers,
in particular also siloxane-based elastomers (cf. WO 01/47490, especially page 7, line 19 – page 15, line
15).
For these routes of administration, the compounds described herein can be administered in suitable dosage
forms.
Quick-release and/or modified-release dosage forms functioning according to the prior art are suitable for
oral administration, containing the compounds described herein in crystalline and/or amorphous and/or
dissolved form, e.g. tablets (uncoated or coated tablets, for example with enteric coatings or delayed-
dissolving or insoluble coatings, which control the release of the compound described herein), tablets or
films/wafers that quickly disintegrate in the oral cavity, films/lyophilizates, capsules (for example hard-
gelatin or soft-gelatin capsules), coated tablets, granules, pellets, powders, emulsions, suspensions,
aerosols or solutions.
Parenteral application can take place while avoiding an absorption step (e.g. intravenous, intraarterial,
intracardial, intraspinal or intralumbar) or with inclusion of absorption (e.g. intramuscular, subcutaneous,
intradermal, percutaneous or intraperitoneal). Injection and infusion preparations in the form of solutions,
suspensions, emulsions, lyophilizates or sterile powders, among others, are suitable as dosage forms for
parenteral administration.
For the other routes of administration, the following are suitable, e.g. inhalation dosage forms (including
powder inhalers, nebulizers), nasal drops, solutions, and sprays; tablets for lingual, sublingual or buccal
administration, films/wafers or capsules, suppositories, ear or eye preparations, vaginal capsules, aqueous
suspensions (lotions, shaking mixtures), lipophilic suspensions, ointments, creams, transdermal
therapeutic systems (for example patches), milk, pastes, foams, dusting powders, implants or stents.
The compounds described herein can be converted to the aforementioned dosage forms. This can be
carried out in a manner that is known per se, by mixing with inert, non-toxic, pharmaceutically suitable
excipients. These excipients include, among others, carrier substances (for example microcrystalline
cellulose, lactose, mannitol), solvents (e.g. liquid polyethylene glycols), emulsifiers and dispersants or
wetting agents (for example sodium dodecylsulphate, polyoxysorbitan oleate), binders (for example
polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers (e.g. antioxidants,
for example ascorbic acid), colouring matter (e.g. inorganic pigments, for example iron oxides) and taste
and/or odour correctants.
Experimental part
The percentages in the following tests and examples are, unless stated otherwise, percentages by weight;
parts are parts by weight. Proportions of solvents, dilution ratios and concentration figures for liquid/liquid
solutions always refer to volume.
The following examples serve to explain the invention without limiting it in any way.
Example 1: Synthesis path of compound 1
(11β,17β)Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone
OH S
O OH
g of the compound described in example 1b) was dissolved in a mixture of 140 ml THF and 140 ml
methanol. A solution of 20 g Oxone in 94 ml water was slowly added dropwise at 0°C. Then it was stirred
for a further 3.5 hours at 0°C. Then a mixture of water and dichloromethane was added to the reaction
mixture. The phases were separated and the aqueous phase was extracted several times with
dichloromethane. The combined organic phases were washed with saturated aqueous sodium chloride
solution, dried over sodium sulphate and concentrated under vacuum. The raw product was purified by
silica gel chromatography. This gave 3.8 g of the title compound.
H-NMR (300 MHz, CDCl ): δ= 7.86 d (2H); 7.40 d (2H); 5.81 sbr (1H); 4.50 dbr (1H); 3.07 s (3H); 0.51 s
(3H).
Example 2: Dose-effect of 84 days treatment with compound 1
Randomized Study population:
1. Healthy female subjects, sterilized by tubal ligation
2. Age at screening: 18 - 45 years
3. Body mass index (BMI) at screening: ≥ 18 and ≤ 32 kg/m²
4. At least 3 consecutive regular menstrual cycles with a cycle length of 24 – 35 days before first
screening examination according to the subject’s history
. Absence of clinically relevant abnormal findings in the pre-treatment endometrial biopsy
6. Adequate venous access (frequent blood sampling)
Protocol:
Table 1: Treatment dosage with compound 1
Dose Treatment (Dose Amount / route of administration Cumulative dose No. of
level compound 1) for per subject subjects
84 days treated
A 0.1 mg 1 tablet 0.1 mg compound 1and 3 8.4 mg 10
tablets placebo once daily per os
B 0.5 mg 1 tablet 0.5 mg compound 1and 3 42 mg 10
tablets placebo once daily per os
C 1 mg 2 tablets 0.5 mg compound 1and 2 84 mg 10
tablets placebo once daily per os
D 2 mg 4 tablets 0.5 mg compound 1once 168 mg 10
daily per os
E 5 mg 1 tablet 5 mg compound 1and 3 420 mg 10
tablets placebo once daily per os
P Placebo 4 tablets placebo once daily per os 0 mg 10
The subject had to start the intake of the study drugs on the first or second day of menstrual bleeding after
the pre-treatment cycle. The pre-treatment cycle started on the first day of the subject’s menstrual bleeding
after screening examinations had shown that the subject was eligible for further participation. After the pre-
treatment cycle treatment was started. The treatment period started with the first and ended with the last
intake of compound 1. For each intake day the subject received one bottle containing 4 tablets. The
number of tablets taken and the intake time had to be documented in the diary.
The evaluation of bleeding pattern was based on a daily self-assessment of the bleeding intensity by the
subject. These assessments were categorized as defined below. The subjects were provided with an
explanation of the categories in local language, and were asked to document the bleeding intensity in their
diaries accordingly (one entry per day).
Administration of compound 1 occurred during 84 days (multiple doses administration).
Table 2: Bleeding pattern categories
Results:
Results of the bleeding pattern is shown in figure 1 (posterior of non-blrrding (per protocol set).
It was observed that compound 1 caused a marked and dose-dependent reduction in the number of days
of bleeding during the treatment period. After administration of 0.5 mg of compound 1, three (3) out of
eleven (11) subjects (27 %) had no further bleeding during the treatment period of 84 days. 50% of dose-
dependent reduction of bleeding is obseverd with a dosage of 0.7 mg. Clear stagnation appears around 2
mg and from 2 mg up to 5 mg a saturation is observed around 95%.
Example 3: Return of bleeding after end of treatment (84 days) with compound 1
Randomized Study population:
As described in example 2.
Protocol:
The first day of bleeding after the end of the treatment was marked.
Results
Subjects of the study treated with 2 mg of compound 1 during 84 days show a delayed return of bleeding
with a mean of 25 days. A delayed return of bleeding after treatment leads to longer free bleeding periods
per year for the subject. One subject showed a delayed return of bleeding after treatment of about 52
days.
All results are in table 3 below.
Table 3: Number of days until onset of bleeding after end of treatment (mean ± SD, min – max; PPS, n =
67).
Plac 0.1 mg 0.5 mg 1 mg 2 mg 5 mg
(n = 12) (n = 11) (n = 11) (n = 10) (n = 12) (n = 11)
Number of days until
9.8 ± 8 12.2 ± 9.9 14.8 ± 10.2 20.3 ± 6.2 25.8 ± 11.1 20.9 ± 10.9
first bleeding after end
(1 – 23) (3 – 35) ( 1 – 28) (8 – 28) (9 – 52) (1 – 38)
of treatment
Plac: Placebo
Example 4: Measurement of endometrial thickness during and after treatment with compound 1
Randomized Study population
As described in example 2.
Protocol:
The endometrial thickness was measured in the medio-sagittal section as double-layer in millimeters using
transvaginal ultrasound.
Results:
Subjects of the study treated with 2 mg of compound 1 during 84 days show a lower maximum thickness
of the endometrium compared to other dosages of compound 1. Further, the observed results of the
subjects of said group are more consistent than other dosage groups.
See figure 2 (Box plot for maximum endometrial thickness within treatment epoch).
Bay means compound 1.
Example 5: Ovulation inhibition: Follicle size, Estradiol (E2), Progesterone (P)
Protocol: Randomized Study population of healthy female subjects as described in example 2 above.
Blood samples were obtained from healthy female subjects for the determination of Estradiol (E2),
Progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH) in serum and taken at
the same time points as listed below during the pre-treatment cycle, the treatment and follow-up cycle.
Transvaginal ultrasound (TVU) was used to monitor ovarian follicular growth during pretreatment (days 9
and 21), treatment (days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84) and follow-up cycle (days 9 and 21).
Results:
Table 4 shows the number and percentage of subjects, classified according to the maximum follicle size
and Estradiol (E2) and Progesterone (P) values during the treatment period (number of subjects n = 69)
During treatment, maximum diameters of Follicle-like structures (FLS) were between 13 and 30 mm in the
majority of subjects of all treatment groups (including placebo).
No ovulation occurred in most of the subjects receiving dosages ≥ 0.5 mg of compound 1 during subject
treatment of 84 days (i.e. progesterone value < 1.57 µg/L).
Table 4
Claims (11)
1. Use of (11β,17β)Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dien- 3-one or salts thereof in the manufacture of a medicament for treatment and/or prophylaxis of a gynaecological disease, wherein the medicament comprises about 1 to 5 mg of (11β,17β) 5 Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone.
2. The use according to claim 1, wherein the medicament comprises about 1 to 4 mg of (11β,17β)- 17-Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone.
3. The use according to claim 1 or 2, wherein the medicament comprises about 2 to 4 mg of (11β,17β)Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone. 10
4. The use according to any one of claims 1 to 3, wherein the medicament comprises about 2 mg of (11β,17β)Hydroxy[4-(methylsulphonyl)phenyl](pentafluoroethyl)estra-4,9-dienone.
5. The use according to any one of claims 1 to 4, wherein the medicament additionally comprises a pharmaceutically acceptable carrier.
6. The use according to any one of claims 1 to 5, wherein the medicament is in a form of an oral 15 dosage.
7. The use according to claim 6, wherein the dosage form is a tablet or a capsule.
8. The use according to any one of claims 1 to 7, wherein the gynaecological disease is characterized by excessive uterine bleeding.
9. The use according to any one of claims 1 to 8, wherein the gynaecological disease is selected 20 from the group consisting of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis and excessive menstrual bleeds.
10. The use according to any one of of claims 1 to 9, wherein the gynaecological disease is fibroids of the uterus (myomas, uterine leiomyoma).
11. The use according to any one of claims 1 to 10, substantially as herein described with reference to 25 any example thereof .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ750686A NZ750686B2 (en) | 2013-04-11 | 2014-04-09 | Progesterone receptor antagonist dosage form |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13163417 | 2013-04-11 | ||
EP13163417.2 | 2013-04-11 | ||
PCT/EP2014/057101 WO2014166971A1 (en) | 2013-04-11 | 2014-04-09 | Progesterone receptor antagonist dosage form |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ712670A NZ712670A (en) | 2020-10-30 |
NZ712670B2 true NZ712670B2 (en) | 2021-02-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220143045A1 (en) | Progesterone receptor antagonist dosage form | |
US20140288035A1 (en) | 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17b-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis | |
CZ278094A3 (en) | Competitive progesteron antagonist and use thereo competitive progesteron antagonist and use thereof f | |
US7378406B2 (en) | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases | |
JP2021098702A (en) | Selective Progesterone Receptor Modulator (SPRM) Regimen | |
AU2002218243A1 (en) | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases | |
US20190022111A1 (en) | ESTROGEN RECEPTOR Beta PARTIAL AGONIST HAVING ESTROGEN RECEPTOR Alpha INHIBITORY EFFECT, AND GYNECOLOGICAL DISEASE THERAPEUTIC AGENT USING SAME | |
NZ712670B2 (en) | Progesterone receptor antagonist dosage form | |
NZ750686B2 (en) | Progesterone receptor antagonist dosage form | |
NZ750686A (en) | Progesterone receptor antagonist dosage form | |
WO2020261602A1 (en) | Pharmaceutical composition | |
ZA200303793B (en) | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases. |